Anti-SPARC antibody (ab55847)
Key features and details
- Rabbit polyclonal to SPARC
- Suitable for: IHC, ELISA, WB
- Reacts with: Mouse, Human
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-SPARC antibody
See all SPARC primary antibodies -
Description
Rabbit polyclonal to SPARC -
Host species
Rabbit -
Tested applications
Suitable for: IHC, ELISA, WBmore details -
Species reactivity
Reacts with: Mouse, Human -
Immunogen
Synthetic peptide derived from the human SPARC protein.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
Preservative: 0.08% Sodium azide
Constituent: PBS -
Concentration information loading...
-
Purification notes
Purified by SAS precipitation. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab55847 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration. Predicted molecular weight: 35 kDa.
PubMed: 19509023. |
Notes |
---|
IHC
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. Predicted molecular weight: 35 kDa. PubMed: 19509023. |
Target
-
Function
Appears to regulate cell growth through interactions with the extracellular matrix and cytokines. Binds calcium and copper, several types of collagen, albumin, thrombospondin, PDGF and cell membranes. There are two calcium binding sites; an acidic domain that binds 5 to 8 Ca(2+) with a low affinity and an EF-hand loop that binds a Ca(2+) ion with a high affinity. -
Sequence similarities
Belongs to the SPARC family.
Contains 1 EF-hand domain.
Contains 1 follistatin-like domain.
Contains 1 Kazal-like domain. -
Developmental stage
Expressed at high levels in tissues undergoing morphogenesis, remodeling and wound repair. -
Cellular localization
Secreted > extracellular space > extracellular matrix > basement membrane. In or around the basement membrane. - Information by UniProt
-
Database links
- Entrez Gene: 6678 Human
- Entrez Gene: 20692 Mouse
- Omim: 182120 Human
- SwissProt: P09486 Human
- SwissProt: P07214 Mouse
- Unigene: 111779 Human
- Unigene: 708558 Human
- Unigene: 291442 Mouse
-
Alternative names
- AA517111 antibody
- Basement membrane protein 40 antibody
- Basement-membrane protein 40 antibody
see all
Protocols
Datasheets and documents
-
Datasheet download
References (9)
ab55847 has been referenced in 9 publications.
- Hatori T et al. SPARC is a decoy counterpart for c‑Fos and is associated with osteoblastic differentiation of bone marrow stromal cells by inhibiting adipogenesis. Mol Med Rep 27:N/A (2023). PubMed: 36633137
- Kalashnikova I et al. Ceria-based nanotheranostic agent for rheumatoid arthritis. Theranostics 10:11863-11880 (2020). PubMed: 33204316
- Xu J et al. Differential Protein Expression between Cystic and Solid Vestibular Schwannoma Using Tandem Mass Tag-Based Quantitative Proteomic Analysis. Proteomics Clin Appl 14:e1900112 (2020). PubMed: 32157794
- Xu J et al. Identification of Predictive Proteins and Biological Pathways for the Tumorigenicity of Vestibular Schwannoma by Proteomic Profiling. Proteomics Clin Appl 13:e1800175 (2019). PubMed: 31120176
- Liu L et al. Secreted Protein Acidic and Rich in Cysteine Mediated Biomimetic Delivery of Methotrexate by Albumin-Based Nanomedicines for Rheumatoid Arthritis Therapy. ACS Nano 13:5036-5048 (2019). PubMed: 30978282
- Wang Q et al. Silencing of SPARC represses heterotopic ossification via inhibition of the MAPK signaling pathway. Biosci Rep 39:N/A (2019). PubMed: 31548362
- Farrokhi E et al. Effect of Oxidized Low Density Lipoprotein on the Expression of Runx2 and SPARC Genes in Vascular Smooth Muscle Cells. Iran Biomed J 19:160-4 (2015). PubMed: 26025968
- Liu Y et al. Apratoxin a reversibly inhibits the secretory pathway by preventing cotranslational translocation. Mol Pharmacol 76:91-104 (2009). PubMed: 19403701
- Kos K et al. Regulation of the fibrosis and angiogenesis promoter SPARC/osteonectin in human adipose tissue by weight change, leptin, insulin, and glucose. Diabetes 58:1780-8 (2009). WB ; Human . PubMed: 19509023